Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.
abacavir/lamivudine/zidovudine
AZL30006
NCT00043888
Infection, Human Immunodeficiency Virus
Phase 3
 
January 2014

Powered by ideaPoint, Inc.